Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.84 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.84 |
| ▸ | HRH1 | P35367 | 5/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184896 | 1.00 | SLC6A2 (0.84) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3326558 | 0.91 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL3326556 | 0.91 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3HRH1 | |
| SCHEMBL3328035 | 0.91 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3330814 | 0.89 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3330815 | 0.89 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3324596 | 0.89 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3192475 | 0.89 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3194471 | 0.89 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3192485 | 0.89 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1950089-A | Morpholine compounds | PFIZER LTD (US) | 2007-04-18 | — | — | CN | claimed |
| CN-1950348-A | Substituted morpholino compounds for the treatment of central nervous system disorders | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | claimed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | claimed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | claimed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | claimed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| CN-1950089-A | Morpholine compounds | PFIZER LTD (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1950348-A | Substituted morpholino compounds for the treatment of central nervous system disorders | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1745029-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | SLC6A2 133/4885SLC6A4 114/4885SLC6A3 104/4885 |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | CNR1, OPRM1, HCRTR1 | SLC6A2 124/4885SLC6A4 235/4885SLC6A3 93/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | SLC6A2 201/4885SLC6A4 350/4885SLC6A3 729/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | SLC6A2 109/4885SLC6A4 113/4885SLC6A3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.